Announcements
- Vaxcyte Appoints John Furey to Board of Directors
- Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
- Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
- Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
- Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
- Vaxcyte Announces Pricing of $750 Million Public Offering
- Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
More ▼
Key statistics
As of last trade Vaxcyte Inc (5VA:FRA) traded at 70.50, -6.62% below its 52-week high of 75.50, set on Feb 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 70.50 |
---|---|
High | 70.50 |
Low | 70.50 |
Bid | 70.50 |
Offer | 71.50 |
Previous close | 71.50 |
Average volume | 285.67 |
---|---|
Shares outstanding | 108.80m |
Free float | 106.20m |
P/E (TTM) | -- |
Market cap | 8.27bn USD |
EPS (TTM) | -4.22 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 07:04 BST.
More ▼